Promise and pitfalls of administrative data in evaluating pregnancy outcomes-Reference-Cited by-同舟云学术

Promise and pitfalls of administrative data in evaluating pregnancy outcomes

Published:2007 Issue:11 Volume:16 Page:1181-1183
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidem. Drug Safe.

Author:

Andrews Elizabeth B.,Tennis Patricia

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference5 articles.

1. Paroxetine in the first trimester and the prevalence of congenital malformations

2. Bupropion in pregnancy and the prevalence of congenital malformations

3. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy

4. First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects

5. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Establishing Pregnancy Exposure Registries. August 2002. http://www.fda.gov/cder/ guidance/index.htm. Accessed August 13, 2007.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maternal and neonatal outcomes after benzodiazepine and benzodiazepine agonist exposure during pregnancy in women with mental disorders;British Journal of Clinical Pharmacology;2023-06-07

2. Measuring Female Veterans' Prepregnancy Wellness Using Department of Veterans Affairs' Health Record Data;Obstetrics & Gynecology;2021-02-03

3. Validation of algorithms to estimate gestational age at birth in the Medicaid Analytic eXtract—Quantifying the misclassification of maternal drug exposure during pregnancy;Pharmacoepidemiology and Drug Safety;2020-09-09

4. Selective serotonin reuptake inhibitor use patterns among commercially insured US pregnancies (2005–2014);Archives of Women's Mental Health;2020-03-28

5. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs;Neurology;2019-06-12